Hepta refractory multiple myeloma is marked by antigen loss, genomic complexity, and 12.8 month median survival in multi centre data.

For patients with newly diagnosed multiple myeloma (NDMM) receiving dexamethasone induction, dose reductions do not negatively impact survival, according to a study published online Jan. 2 in Blood.

Your survival rate for multiple myeloma is likely higher in earlier stages. Younger people often have better outcomes due to their resilience to intensive treatments. Advances in treatment have ...

Success is no longer just about prolonging survival, but about enabling patients to live well after cancer, with fewer ...

Patient-reported physical function scores are significant predictors of survival and adverse events in multiple myeloma treatment. Physical function has a stronger correlation with patient outcomes ...

"Medical Journeys" is a set of clinical resources reviewed by doctors, meant for physicians and other healthcare professionals as well as the patients they serve. Each episode of this journey through ...

The U.S. Food and Drug Administration (FDA) has accepted a new drug application for iberdomide combined with Darzalex ...

Haznedar R, Akı SZ, Akdemir OU, et al. The role of FDG PET/CT in patients with multiple myeloma is evolving. Earlier studies showed that multiple myeloma lesions with FDG uptake are the metabolically ...

Kyprolis is a type of medicine called a proteasome inhibitor. The proteasome is like the cell's "trash disposal" system. Proteasome inhibitors such as Kyprolis bind to and block the activity of the ...

The FDA has started a priority review of iberdomide as an add-on to Johnson & Johnson and Genmab's anti-CD38 antibody Darzalex (daratumumab) and dexamethasone, a standard regimen for relapsed or ...

How Does Sarclisa Work in Multiple Myeloma? Sarclisa is a type of medicine called a monoclonal antibody that is also known as a targeted therapy or an immunotherapy. It works by targeting a specific ...